Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa
Alonso Sánchez-Cruz(Universidad Complutense de Madrid), Catalina Hernández‐Sánchez(Centro de Investigaciones Biológicas Margarita Salas), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Carmen Gil(Instituto de Salud Carlos III), Enrique J. de la Rosa(Instituto de Salud Carlos III), Beatriz Villarejo‐Zori(Centro de Investigaciones Biológicas Margarita Salas), Josefa Zaldívar-Díez(Centro de Investigaciones Biológicas Margarita Salas), Miguel Marchena(Centro de Investigaciones Biológicas Margarita Salas), Ignacio Lizasoaín(Universidad Complutense de Madrid)
Cited by 42
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293